Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) have received an average recommendation of “Moderate Buy” from the eight ratings firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $8.20.

A number of brokerages have recently issued reports on WHWK. Leerink Partners assumed coverage on shares of Whitehawk Therapeutics in a report on Monday, July 13th. They set an “outperform” rating and a $9.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Whitehawk Therapeutics in a report on Wednesday, September 2nd. B. Riley Financial assumed coverage on Whitehawk Therapeutics in a research report on Thursday, June 25th. They issued a “buy” rating and a $10.00 price objective for the company. Finally, Wall Street Zen raised Whitehawk Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th.

Whitehawk Therapeutics Trading Up 1.0%

Shares of WHWK opened at $4.11 on Friday. Whitehawk Therapeutics has a 12-month low of $1.80 and a 12-month high of $5.49. The firm has a 50-day moving average price of $4.29 and a 200 day moving average price of $4.10. The firm has a market capitalization of $234.31 million, a P/E ratio of -3.67 and a beta of 0.81.

Whitehawk Therapeutics (NASDAQ:WHWK) last issued its earnings results on Thursday, August 6th. The company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.10. Equities research analysts predict that Whitehawk Therapeutics will post -1.1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Whitehawk Therapeutics

A number of hedge funds have recently modified their holdings of the business. Orbimed Advisors LLC acquired a new stake in Whitehawk Therapeutics in the 3rd quarter valued at approximately $7,915,000. Acuta Capital Partners LLC acquired a new position in Whitehawk Therapeutics during the third quarter worth $6,480,000. KVP Capital Advisors LP purchased a new position in shares of Whitehawk Therapeutics during the fourth quarter worth $5,242,000. Yu Fan purchased a new position in shares of Whitehawk Therapeutics during the third quarter worth $3,933,000. Finally, BlackRock Inc. acquired a new stake in shares of Whitehawk Therapeutics in the second quarter valued at $8,807,000. 52.08% of the stock is currently owned by hedge funds and other institutional investors.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.